SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is experiencing a massive, sustained short squeeze, with community discussion intensely focused on the stock's parabolic climb and the intense battle between institutional players and short sellers. Market participants are heavily debating the potential for a massive equity offering once the current quiet period expires, while many traders warn of an inevitable and sharp reversal reminiscent of historic meme stock crashes.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to a significant partnership with NVIDIA to integrate its QNX safety-certified OS into advanced AI-driven industrial and robotics platforms, marking a shift from legacy perceptions to a key player in physical AI. Community sentiment remains highly bullish, with investors focusing on the company's turnaround, strengthened fundamentals, and the expectation of long-term growth as the stock reclaims multi-year highs on heavy volume.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility following allegations of market manipulation and insider dumping, leading the community to heavily debate whether the token is a classic pump-and-dump scheme or a high-risk opportunity for a short squeeze. Investors are currently split between those aggressively trying to scalp a 'dead cat bounce' and those warning of further downside risks following the dramatic decline from its recent peak.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing a massive surge in volume and bullish sentiment as the stock benefits from its aggressive Bitcoin acquisition strategy and the proposal for semi-monthly dividends on its preferred shares. Community members are actively debating the potential for a major short squeeze, with many pointing to Bitcoin's recent strength and the stock's position as a levered proxy as catalysts for a move toward higher resistance levels.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is seeing intense market activity following a strategic agreement to acquire the Serra Verde rare earth mine in Brazil, a move analysts view as a significant step toward domestic supply chain independence. While some investors remain cautious regarding potential dilution, the community is actively debating the company's long-term positioning as a vertically integrated producer versus the immediate risks posed by share issuance.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is facing intense volatility and downward pressure following news of a proposed equity offering to expand production capacity for its indium phosphide substrates. While community members are polarized between those betting on long-term AI infrastructure demand and those labeling the stock a speculative bubble prone to dilution, the active conversation remains dominated by concerns over the potential share count increase and skepticism regarding the company's valuation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon stock is seeing heightened investor interest following a massive commitment to expand its AI infrastructure through a multi-billion dollar investment and cloud deal with Anthropic. The market is actively discussing the strategic move as a way for Amazon to secure a long-term demand anchor for its AWS and custom chip ecosystem, leading to bullish sentiment regarding the company's deepening role in the AI compute stack.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid heightened institutional interest, with the community actively speculating on the potential impacts of the Clarity Act and the resolution of regional geopolitical tensions. Investors remain focused on accumulation strategies while debating the asset's long-term utility versus its recent range-bound price action.

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Alterity Therapeutics is trending following the U.S. FDAs grant of Fast Track Designation for its lead drug candidate, ATH434, a development that investors believe positions the company for accelerated approval and potential M&A interest. The community is actively discussing the strategic addition of new board members with big pharma backgrounds and debating whether the current low market capitalization makes the firm an ideal acquisition target for major pharmaceutical companies.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4Chan is trending as community members position it as the "Bitcoin of memecoins," emphasizing its cultural origin and high-risk, high-reward tokenomics. Investors are actively debating its potential for generational wealth, with discussions focused on accumulating tokens during price volatility to prepare for expected future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$COGT Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM 
 
Cogent Biosciences announced that the U.S. FDA has accepted its New Drug Application for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act target action date of December 30, 2026. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues. Clinical results from the pivotal SUMMIT trial with bezuclastinib in NonAdvSM patients demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. Data from the SUMMIT trial through 48 weeks showcased a clear and continued deepening of symptomatic improvement over time, supporting the potential for sustained clinical benefit with longer duration of therapy. In addition, results also showed the benefit of bezuclastinib in populations with high unmet need and bezuclastinib&#39;s impact on bone mineral density as well as evidence of disease modification.  
 
Across the SUMMIT trial, bezuclastinib demonstrated a favorable safety and tolerability profile, supporting its potential for chronic use in patients with NonAdvSM. Completion of the NDA submission for bezuclastinib in patients with Gastrointestinal Stromal Tumors who have received prior treatment with imatinib remains on track for April 2026. The GIST submission was initiated under Real-Time Oncology Review, and bezuclastinib received Breakthrough Therapy Designation in this indication. The NDA submission for bezuclastinib in patients with Advanced Systemic Mastocytosis remains on track for the first half of 2026.

Enehildo Badillo

StockTwits Web

Cogent Biosciences Inc

 Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM 
 
Cogent Biosciences announced that the U.S. FDA has accepted its New Drug Application for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act target action date of December 30, 2026. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues. Clinical results from the pivotal SUMMIT trial with bezuclastinib in NonAdvSM patients demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. Data from the SUMMIT trial through 48 weeks showcased a clear and continued deepening of symptomatic improvement over time, supporting the potential for sustained clinical benefit with longer duration of therapy. In addition, results also showed the benefit of bezuclastinib in populations with high unmet need and bezuclastinib's impact on bone mineral density as well as evidence of disease modification.  
 
Across the SUMMIT trial, bezuclastinib demonstrated a favorable safety and tolerability profile, supporting its potential for chronic use in patients with NonAdvSM. Completion of the NDA submission for bezuclastinib in patients with Gastrointestinal Stromal Tumors who have received prior treatment with imatinib remains on track for April 2026. The GIST submission was initiated under Real-Time Oncology Review, and bezuclastinib received Breakthrough Therapy Designation in this indication. The NDA submission for bezuclastinib in patients with Advanced Systemic Mastocytosis remains on track for the first half of 2026.